Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
8
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Annovis Bio Inc market cap is $44.12M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Annovis Bio Inc 52 week high is $5.50 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Annovis Bio Inc 52 week low is $0.6161 as of November 22, 2026.
Annovis Bio Inc stock price today is $0.7113.
Annovis Bio Inc stock price yesterday was $0.7484.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Annovis Bio Inc's P/E ratio is -0.43.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Annovis Bio Inc P/B ratio is -2.2943.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Annovis Bio Inc 50-day moving average is $1.05.